Reference infliximab | Biosimilar infliximab | P-value | |
---|---|---|---|
Duration = 6 months | Duration = 15.8 months | ||
Death | 0 | 1 | – |
Infusion related adverse events | 1 | 1 | – |
Serious adverse events | 2 | 3 | – |
PGA, mean (SD) | 28.3 (23.2) | 35.2 (25.6) | 0.111 |
HAQ, median (range) | 0.38 (0–2.63) | 0.69 (0–2.63) | 0.111 |
Pain level, mean (SD) | 28.8 (23.1) | 38.1 (26.3) | 0.028 |
CRP, median (range) | 1.95 (0.6–25.9) | 4 (0.6–21.3) | 0.001 |
Dose in Mg, mean (SD) | 298.2 (110.5) | 302.3 (125.4) | 0.494 |
Flares No. | 10 | 14 | 0.177 |